Personal Genome Diagnostics Inc. and KingMed Diagnostics, announced that they have entered into a strategic partnership for the PGDx elio tissue complete assay. KingMed Diagnostics brings substantial patient reach, encompassing 37 laboratories covering more than 21,000 hospitals and clinics. This partnership provides PGDx and KingMed Diagnostics the opportunity to serve the clinical trial screening needs of pharmaceutical partners in the Asian market through testing sites in mainland China and Hong Kong. In time and as a result of contributing data from these studies, the partners expect to also serve the clinical testing needs of patients and physicians in those geographies upon the appropriate regulatory approvals of the PGDx elio assays. The PGDx elio tissue complete panel is a 500+ gene test for somatic alterations that detects single nucleotide variants (SNVs), small insertion/deletions (indels), amplifications, rearrangements, microsatellite instability (MSI) and tumor mutational burden (TMB). The use of TMB and MSI for the identification of cancer patients whose tumors may be likely to respond to immune checkpoint inhibitor therapy has recently been investigated in clinical trials (TMB) and approved (MSI) by the U.S. Food and Drug Administration (FDA). Under the agreement, the companies will work together to establish KingMed Diagnostics as a qualified clinical trial testing site for the PGDx elio tissue complete assay, addressing significant demand, with a focus on TMB and other variants of relevance for Immuno-Oncology drug development. Once approved by the appropriate regulatory bodies, this partnership could also enable local access to this new genomic oncology technology for a significant number of patients facing their cancer battle in China.